You are here: Industry Insights > lymphoma

News List

FDA Grants BeiGene’s Lymphoma Treatment Priority Review americanpharmaceuticalreview
August 23, 2019
BeiGene, Ltd. has announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for zanubrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Medicare to Cover CAR-T Therapy for Leukemia, Lymphoma drugs
August 09, 2019
A breakthrough gene therapy will be covered for certain types of lymphoma and leukemia, Medicare says.
ASCT May Offer Alternative for Tx of High-Risk Follicular Lymphoma drugs
July 26, 2019
Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk...
Allergan Recalls Textured Breast Implants Linked to Lymphoma drugs
July 25, 2019
Allergan's textured breast implants will be recalled due to their link to a rare cancer, the U.S. Food and Drug Administration announced Wednesday.
Cellectar Receives FTD for Diffuse Large B-Cell Lymphoma Treatment contractpharma
July 10, 2019
Drug conjugate, CL131, delivers cytotoxic radiation directly and selectively to cancer cells.
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma worldpharmanews
June 20, 2019
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma.
TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting drugs
June 13, 2019
TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting.
FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma drugs
June 11, 2019
FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma.
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma drugs
May 29, 2019
FDA Approves Revlimid (lenalidomide) In Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma.
Cellectar Gains FDA Fast Track for CLR 131 in MM contractpharma
May 16, 2019
CLR 131 is being evaluated in a Phase II study in patients with relapsed or refractory multiple myeloma and other select B-Cell lymphomas.

Previous page 1 2 3 4 5 Next page